2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2027

Development of a Dual Energy Computed Tomography Scoring System for Measurement of Urate Deposition in Gout
Abstract Number: 415

Development of a Juvenile Systemic Sclerosis Response Index (JSSRI)
Abstract Number: 1712

Development of a Novel SI Joint CT Score for Diagnosis of Axial Spondylitis
Abstract Number: 708

Development of an Activity Disease Score in Patients with Uveitis
Abstract Number: 870

Development of an Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Patient-Reported Outcome Measure: Identification of Salient Themes and Candidate Questionnaire Item Development
Abstract Number: 943

Development of an Internationally Agreed Minimal Dataset for Juvenile Dermatomyositis (JDM) for Clinical and Research Use
Abstract Number: 926

Development of an Ultrasound Joint Inflammation Score for Rheumatoid Arthritis through a Data-Driven Approach
Abstract Number: 2076

Development of Lupus Nephritis: Preclinical Evaluation of Patients Who Subsequently Develop Systemic Lupus Erythematosus Demonstrate Elevation of Select Soluble Mediators Prior to and at Disease Classification in Patients with Nephritis
Abstract Number: 29

Development of Multimorbidity in Patients with Newly Diagnosed Rheumatoid Arthritis – a Population-Based Study
Abstract Number: 1635

Development of New Bioassay System Measuring Inhibitory Strength of IL-6/STAT3 Signal Under Tocilizumab Treatment in Rheumatoid Arthritis Patients
Abstract Number: 999

Development of Quality Indicators for Hip and Knee Arthroplasty Rehabilitation
Abstract Number: 1402

Development of Systemic Juvenile Idiopathic Arthritis Manifestations Following Remission of Hemophagocytic Lymphohistiocytosis
Abstract Number: 1904

Development of the Mawdsley Calcinosis Questionnaire (MCQ) Version 1 – a Patient-Reported Outcome Measure (PROM) for Systemic Sclerosis Related Calcinosis (SSc-Ca)
Abstract Number: 3179

Diagnosing Childhood Small Vessel CNS Vasculitis
Abstract Number: 1596

Diagnosis of Carotid Plaque By 4 Cardiovascular Risk Scores in Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].